查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1575000

研究性新藥 CDMO 市場，按服務類型、按藥物類型、按階段、按最終用戶、按國家和地區分類 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Investigational New Drug CDMO Market, By Service Type, By Drug Type, By Phase, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 301 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年研究用新藥CDMO市場規模為48.9032億美元，2024年至2032年複合年成長率為6.90%。

研究性新藥 CDMO 市場-市場動態

臨床試驗數量的增加加速了研究性新藥 CDMO 市場的成長

臨床試驗數量的增加顯著加速了研究性新藥 (IND) CDMO 市場的成長。據世界衛生組織稱，2022 年全球註冊臨床試驗超過 40,000 項，反映出研究活動激增。美國 FDA 也報告 IND 申請量穩定成長，去年提交的申請數量達到近 5,000 份。這種上升是由生物技術的進步和新療​​法的緊迫性所推動的，特別是在腫瘤學和罕見疾病等領域。 Catalent 和 Thermo Fisher Scientific 等主要參與者正在擴大其設施和能力，以滿足不斷成長的需求，為藥物開發和製造提供量身定做的解決方案。此外，FDA 即時腫瘤學審查計畫等措施旨在加快臨床試驗流程，進一步推動對高效 CDMO 服務的需求。隨著製藥公司擴大尋求與 CDMO 合作以簡化其開發管道，市場有望持續擴張。

研究性新藥 CDMO 市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032 年）每年將以 6.90% 左右的複合年成長率成長

根據服務類型細分，預計藥品製造將在 2023 年顯示最大的市場佔有率

根據藥物類型細分，生物製劑是2023年的主導類型

按期數細分，2023年二期為主導類型

按地區分類，北美是 2023 年的主要收入來源

研究性新藥 CDMO 市場-區隔分析：

全球研究性新藥 CDMO 市場根據服務類型、藥物類型、階段、最終用戶和區域進行細分。

根據服務類型，市場分為四類：原料藥製造、藥品製造、包裝和標籤以及臨床試驗供應。藥品製造因其在開發臨床試驗最終配方中的關鍵作用而處於領先地位。原料藥製造緊隨其後，臨床試驗供應和包裝與標籤分別排名第三和第四。

根據藥物類型，市場分為兩類：小分子和生物製劑。生物製劑因其需求不斷增加且製造製程複雜性而佔據主導地位。小分子緊隨其後，仍然佔市場的很大一部分，特別是對於傳統藥品和學名藥而言。

研究性新藥 CDMO 市場 - 地理洞察

研究性新藥 (IND) CDMO 市場表現出顯著的地理多樣性，其中北美處於領先地位，特別是由於美國強大的製藥格局。 FDA 報告 2022 年有超過 5,000 份 IND 申請，凸顯了該地區活躍的臨床試驗環境。 Lonza 和 Catalent 等主要 CDMO 廠商已在該地區建立了廣泛的設施，以滿足不斷成長的需求。歐洲緊追在後，德國和英國等國家大力投資生物製藥研究；歐洲藥品管理局支持多項簡化臨床試驗核准的舉措，進一步鼓勵 CDMO 合作夥伴關係。在亞太地區，在越來越多的臨床試驗和有利的監管環境的推動下，中國和印度等國家正在成為主要參與者； 2022 年，光是中國的臨床試驗註冊量就成長了 35%。這種多樣化的區域格局凸顯了 IND CDMO 市場的全球成長潛力。

研究性新藥 CDMO 市場-競爭格局：

研究性新藥 (IND) CDMO 市場的競爭格局以各個地區的積極參與為標誌。北美是領先地區，是賽默飛世爾科技 (Thermo Fisher Scientific) 和康泰倫特 (Catalent) 等主要參與者的所在地，它們在處理 IND 項目方面利用先進技術和豐富經驗。根據 FDA 報告， IND 申請數量到 2022 年將超過 5,000 份，這凸顯了對這些服務的需求。歐洲也是一個強力的競爭者，Lonza 和 Recipharm 等公司不斷擴大業務以滿足不斷成長的市場需求；德國健全的監管架構和英國的臨床試驗法規對於吸引投資至關重要。在亞太地區，中國和印度生物製藥中心的崛起引人注目，在旨在提高臨床試驗效率的政府舉措的支持下，藥明康德等公司成為主要參與者。據報道，2022 年中國臨床試驗註冊量將成長 35%，進一步凸顯了這個快速發展的市場的競爭動態。

最新進展：

2023 年 10 月，Evaluate 推出了 CDMO Intelligence 解決方案，為合約開發和製造組織 (CDMO) 以及生物製藥公司提供全面的市場洞察。該工具旨在最佳化快速成長的製藥 CDMO 市場的策略，預計到 2028 年將大幅擴張。

2023年10月，Tanvex BioPharma推出Tanvex CDMO，為生物製劑提供全面的合約開發與製造服務。該中心位於聖地牙哥，擁有先進的設施，旨在協助生物製藥公司將產品從研究性新藥 (IND) 狀態推進到上市準備階段。

目錄

第 1 章：研究性新藥 CDMO 市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按服務類型分類的研究性新藥 CDMO 市場片段
    • 按藥物類型分類的研究性新藥 CDMO 市場片段
    • 依階段分類的研究性新藥 CDMO 市場片段
    • 最終用戶研究性新藥 CDMO 市場片段
    • 按國家/地區分類的研究性新藥 CDMO 市場片段
    • 按地區分類的研究性新藥 CDMO 市場片段
  • 競爭洞察

第 3 章：研究性新藥 CDMO 主要市場趨勢

  • 研究性新藥 CDMO 市場促進因素
    • 市場促進因素的影響分析
  • 研究性新藥 CDMO 市場限制
    • 市場限制影響分析
  • 研究性新藥 CDMO 市場機會
  • 研究性新藥 CDMO 市場未來趨勢

第 4 章：研究性新藥 CDMO 產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：研究性新藥 CDMO 市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：研究性新藥 CDMO 市場格局

  • 2023 年研究性新藥 CDMO 市佔率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：研究性新藥 CDMO 市場 - 按服務類型

  • 概述
    • 按服務類型分類的細分市場佔有率分析
    • 原料藥製造
    • 藥品製造
    • 包裝和標籤
    • 臨床試驗供應

第 8 章：研究性新藥 CDMO 市場 - 按藥物類型

  • 概述
    • 按藥物類型分類的細分市場佔有率分析
    • 小分子
    • 生物製品

第 9 章：研究性新藥 CDMO 市場 - 按階段

  • 概述
    • 按階段分類的細分市場佔有率分析
    • 第一階段
    • 第二階段
    • 第三階段

第 10 章：研究性新藥 CDMO 市場 - 按最終用戶

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 製藥公司
    • 生物製藥公司
    • 生技公司

第 11 章：研究性新藥 CDMO 市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美研究性新藥 CDMO 主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按服務類型）
    • 北美市場規模和預測（按藥物類型）
    • 北美市場規模和預測（按階段）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲研究性新藥 CDMO 主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按服務類型）
    • 歐洲市場規模和預測（按藥物類型）
    • 歐洲市場規模與預測（按階段）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區在開發新藥 CDMO 主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模與預測（按服務類型）
    • 亞太地區市場規模和預測（按藥物類型）
    • 亞太地區市場規模及預測（按階段）
    • 亞太地區市場規模和預測（按最終用戶）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲研究性新藥 CDMO 主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模和預測（按服務類型）
    • 拉丁美洲市場規模與預測（按藥物類型）
    • 拉丁美洲市場規模與預測（按階段）
    • 拉丁美洲市場規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲在開發新藥 CDMO 主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按服務類型）
    • 中東和非洲市場規模及預測（按藥物類型）
    • 中東和非洲市場規模及預測（按階段）
    • 中東和非洲市場規模和預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 12 章：主要供應商分析 - 研究性新藥 CDMO 產業

  • 競爭儀表板
  • 公司簡介
    • Almac Group Limited
    • Baxter BioPharma Solutions
    • Boehringer Ingelheim International GmbH
    • Cambrex Corporation
    • Catalent, Inc.
    • Charles River Laboratories International, Inc.
    • CordenPharma International GmbH
    • Fujifilm Diosynth Biotechnologies USA, Inc.
    • Jubilant Life Sciences Limited
    • Lonza Group AG
    • Patheon Inc. (Thermo Fisher Scientific)
    • Piramal Pharma Solutions
    • Recipharm AB
    • Samsung Biologics Co., Ltd.
    • Siegfried Holding AG
    • WuXi AppTec Co., Ltd.
    • Others

第 13 章：360 度分析師視角

第 14 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV3987

REPORT HIGHLIGHT

Investigational New Drug CDMO Market size was valued at USD 4,890.32 Million in 2023, expanding at a CAGR of 6.90% from 2024 to 2032.

The Investigational New Drug (IND) Contract Development and Manufacturing Organization (CDMO) Market focuses on services that support pharmaceutical companies in developing and manufacturing new drug candidates for clinical trials. The increasing number of clinical trials and the demand for specialized manufacturing services are significant factors propelling market growth. Furthermore, the rising investment in biopharmaceutical research and development, with over $200 billion allocated globally in 2022, underscores the need for efficient CDMO partnerships. However, stringent regulatory requirements and the high cost of compliance can restrain market entry for new players. Opportunities are emerging in the biotechnology sector, where the demand for tailored manufacturing solutions is rising; for example, companies like Lonza and WuXi AppTec are expanding their capabilities to cater to the growing biologics market. Additionally, the shift towards personalized medicine is creating a need for more flexible and scalable manufacturing solutions, enhancing the overall potential for CDMOs in the IND space.

Investigational New Drug CDMO Market- Market Dynamics

Increasing Number of Clinical Trials Accelerates Growth of the Investigational New Drug CDMO Market

The increasing number of clinical trials is significantly accelerating the growth of the Investigational New Drug (IND) CDMO Market. According to the World Health Organization, over 40,000 clinical trials were registered globally in 2022, reflecting a surge in research activity. The U.S. FDA has also reported a steady rise in IND applications, reaching nearly 5,000 submissions in the last year. This uptick is driven by advancements in biotechnology and the urgency for new therapies, particularly in areas like oncology and rare diseases. Major players like Catalent and Thermo Fisher Scientific are expanding their facilities and capabilities to meet this rising demand, offering tailored solutions for drug development and manufacturing. Additionally, initiatives such as the FDA's Real-Time Oncology Review program aim to expedite the clinical trial process, further propelling the need for efficient CDMO services. As pharmaceutical companies increasingly seek partnerships with CDMOs to streamline their development pipelines, the market is poised for continued expansion.

Investigational New Drug CDMO Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.90% over the forecast period (2024-2032)

Based on Service Type segmentation, Drug Product Manufacturing was predicted to show maximum market share in the year 2023

Based on Drug Type segmentation, Biologics was the leading type in 2023

Based on Phase segmentation, Phase II was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Investigational New Drug CDMO Market- Segmentation Analysis:

The Global Investigational New Drug CDMO Market is segmented on the basis of Service Type, Drug Type, Phase, End-User, and Region.

The market is divided into four categories based on Service Type: Drug Substance Manufacturing, Drug Product Manufacturing, Packaging & Labeling, and Clinical Trial Supply. Drug Product Manufacturing leads due to its critical role in developing final formulations for clinical trials. Drug Substance Manufacturing follows closely, while Clinical Trial Supply and Packaging & Labeling rank third and fourth, respectively.

The market is divided into two categories based on Drug Type: Small Molecules and Biologics. Biologics take precedence due to their increasing demand and complexity in manufacturing processes. Small Molecules follow, still representing a significant portion of the market, particularly for traditional pharmaceuticals and generic drugs.

Investigational New Drug CDMO Market- Geographical Insights

The Investigational New Drug (IND) CDMO Market exhibits significant geographical diversity, with North America leading, particularly due to the United States' robust pharmaceutical landscape. The FDA reported over 5,000 IND applications in 2022, highlighting the region's active clinical trial environment. Major CDMO players like Lonza and Catalent have established extensive facilities in this region to cater to growing demand. Europe follows closely, with countries like Germany and the UK investing heavily in biopharmaceutical research; the European Medicines Agency supports numerous initiatives to streamline clinical trial approvals, further encouraging CDMO partnerships. In the Asia-Pacific region, countries like China and India are emerging as key players, driven by an increasing number of clinical trials and favorable regulatory environments; China alone saw a 35% rise in clinical trial registrations in 2022. The Indian government has also launched initiatives to enhance its clinical research capabilities, attracting foreign investments and strengthening its CDMO presence. This diverse regional landscape underscores the global potential for growth in the IND CDMO market.

Investigational New Drug CDMO Market- Competitive Landscape:

The Competitive Landscape of the Investigational New Drug (IND) CDMO Market is marked by active engagement across various regions. North America stands out as the leading region, home to major players like Thermo Fisher Scientific and Catalent, which leverage advanced technologies and extensive experience in handling IND projects. The FDA's reported increase in IND applications, exceeding 5,000 in 2022, underscores the demand for these services. Europe is also a strong contender, with companies like Lonza and Recipharm expanding their operations to meet the needs of a growing market; Germany's robust regulatory framework and the UK's Clinical Trial Regulations are pivotal in attracting investments. In the Asia-Pacific region, the rise of biopharmaceutical hubs in China and India is notable, with firms like WuXi AppTec emerging as key players, supported by governmental initiatives aimed at enhancing clinical trial efficiency. China's reported 35% increase in clinical trial registrations in 2022 further highlights the competitive dynamics in this fast-evolving market.

Recent Developments:

In October 2023, Evaluate launched its CDMO Intelligence solution, providing comprehensive market insights for contract development and manufacturing organizations (CDMOs) and biopharma firms. This tool aims to optimize strategies in the rapidly growing pharmaceutical CDMO market, projected to expand significantly through 2028.

In October 2023, Tanvex BioPharma launched Tanvex CDMO, providing comprehensive contract development and manufacturing services for biologics. Located in San Diego, it features advanced facilities and aims to assist biopharmaceutical companies in advancing products from investigational new drug (IND) status to market readiness.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INVESTIGATIONAL NEW DRUG CDMO MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Almac Group Limited
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • CordenPharma International GmbH
  • Fujifilm Diosynth Biotechnologies USA, Inc.
  • Jubilant Life Sciences Limited
  • Lonza Group AG
  • Patheon Inc. (Thermo Fisher Scientific)
  • Piramal Pharma Solutions
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • Siegfried Holding AG
  • WuXi AppTec Co., Ltd.
  • Others

GLOBAL INVESTIGATIONAL NEW DRUG CDMO MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Drug Substance Manufacturing
  • Drug Product Manufacturing
  • Packaging & Labeling
  • Clinical Trial Supply

GLOBAL INVESTIGATIONAL NEW DRUG CDMO MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Small Molecules
  • Biologics

GLOBAL INVESTIGATIONAL NEW DRUG CDMO MARKET, BY PHASE- MARKET ANALYSIS, 2019 - 2032

  • Phase I
  • Phase II
  • Phase III

GLOBAL INVESTIGATIONAL NEW DRUG CDMO MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Biotechnology Firms

GLOBAL INVESTIGATIONAL NEW DRUG CDMO MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Investigational New Drug CDMO Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Investigational New Drug CDMO Market Snippet by Service Type
    • 2.1.2. Investigational New Drug CDMO Market Snippet by Drug Type
    • 2.1.3. Investigational New Drug CDMO Market Snippet by Phase
    • 2.1.4. Investigational New Drug CDMO Market Snippet by End-User
    • 2.1.5. Investigational New Drug CDMO Market Snippet by Country
    • 2.1.6. Investigational New Drug CDMO Market Snippet by Region
  • 2.2. Competitive Insights

3. Investigational New Drug CDMO Key Market Trends

  • 3.1. Investigational New Drug CDMO Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Investigational New Drug CDMO Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Investigational New Drug CDMO Market Opportunities
  • 3.4. Investigational New Drug CDMO Market Future Trends

4. Investigational New Drug CDMO Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Investigational New Drug CDMO Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Investigational New Drug CDMO Market Landscape

  • 6.1. Investigational New Drug CDMO Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Investigational New Drug CDMO Market - By Service Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Service Type, 2023 & 2032 (%)
    • 7.1.2. Drug Substance Manufacturing
    • 7.1.3. Drug Product Manufacturing
    • 7.1.4. Packaging & Labeling
    • 7.1.5. Clinical Trial Supply

8. Investigational New Drug CDMO Market - By Drug Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 8.1.2. Small Molecules
    • 8.1.3. Biologics

9. Investigational New Drug CDMO Market - By Phase

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Phase, 2023 & 2032 (%)
    • 9.1.2. Phase I
    • 9.1.3. Phase II
    • 9.1.4. Phase III

10. Investigational New Drug CDMO Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Pharmaceutical Companies
    • 10.1.3. Biopharmaceutical Companies
    • 10.1.4. Biotechnology Firms

11. Investigational New Drug CDMO Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Investigational New Drug CDMO Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Investigational New Drug CDMO Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Investigational New Drug CDMO Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Investigational New Drug CDMO Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Investigational New Drug CDMO Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Phase, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Investigational New Drug CDMO Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Almac Group Limited
    • 12.2.2. Baxter BioPharma Solutions
    • 12.2.3. Boehringer Ingelheim International GmbH
    • 12.2.4. Cambrex Corporation
    • 12.2.5. Catalent, Inc.
    • 12.2.6. Charles River Laboratories International, Inc.
    • 12.2.7. CordenPharma International GmbH
    • 12.2.8. Fujifilm Diosynth Biotechnologies USA, Inc.
    • 12.2.9. Jubilant Life Sciences Limited
    • 12.2.10. Lonza Group AG
    • 12.2.11. Patheon Inc. (Thermo Fisher Scientific)
    • 12.2.12. Piramal Pharma Solutions
    • 12.2.13. Recipharm AB
    • 12.2.14. Samsung Biologics Co., Ltd.
    • 12.2.15. Siegfried Holding AG
    • 12.2.16. WuXi AppTec Co., Ltd.
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us